EYPT - Rallybio EyePoint in collaboration for geographic atrophy therapy

• Rallybio ( NASDAQ: RLYB ) and EyePoint Pharmaceuticals ( NASDAQ: EYPT ) are in a research collaboration evaluating delivery of the former's complement component 5 (C5) inhibitor using the latter's Durasert technology for intraocular drug delivery.
• The beginning focus will be on geographic atrophy, an advanced form of age-related macular degeneration.
• Financial terms were not disclosed.
• The companies say they hope to develop a long-acting intravitreal insert . The current standard therapy is injected every one to two months.
• Seeking Alpha's Quant Rating views EyePoint ( EYPT ) as a hold with strong marks for valuation and revisions .

For further details see: